MGC Pharmaceuticals Ltd (ASX:MXC)
MGC Pharmaceuticals Ltd (ASX:MXC) is a bio-pharma company developing and supplying affordable, standardised, phytocannabinoid-derived medicines to patients around the world.
MGC Pharma's core strategy is to develop and supply high quality phytocannabinoid-derived medicines to meet the growing demand in Europe, North America and Australasia.
The Company has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline. Employing its ‘Nature to Medicine’ strategy, MGC Pharma has partnered with institutions and academia to optimise cultivation and the development of targeted phytocannabinoid-derived medicines products prior to production in the Company’s manufacturing facility.
MGC Pharma has a number of research collaborations with academic institutions. These have produced research results including the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically-resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution network of commercial partners.